Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannis A van Rossum

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 13, 2014
The effect of prolonged natalizumab treatment on anxiety and safety in JC virus-seropositive MS patients; a follow-up studyJohannis A van Rossum, Anke Vennegoor, Joep Killestein
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 10, 2015
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathyAnke Vennegoor, Johannis A van Rossum, Chris H Polman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 6, 2013
Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patientsJohannis A van Rossum, Anke Vennegoor, Lisanne Balk, et al.
Multiple Sclerosis and Related Disorders|June 23, 2019
Severe cutaneous adverse event in a daclizumab-treated multiple sclerosis patientJohannis A van Rossum, Marieke A D Peters, Paul van der Valk, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2018
gMS-Classifier1 does not predict disability progression in multiple sclerosisJohannis A van Rossum, Joep Killestein, Luisa M Villar, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 26, 2019
Infusion-related events during natalizumab: No need for post-infusion monitoringFloor C Loonstra, Johannis A van Rossum, Zoé LE van Kempen, et al.
Multiple Sclerosis and Related Disorders|September 24, 2019
Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumabJohannis A van Rossum, Zoé L E van Kempen, Louise Schilder, et al.
Journal of Neurology|April 21, 2019
Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturationZoé L E van Kempen, Johannis A van Rossum, Djoeke Doesburg, et al.
Multiple Sclerosis and Related Disorders|February 20, 2021
Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patientsZoé L E van Kempen, Johannis A van Rossum, Erwin Hoogervorst, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 13, 2014
The effect of prolonged natalizumab treatment on anxiety and safety in JC virus-seropositive MS patients; a follow-up studyJohannis A van Rossum, Anke Vennegoor, Joep Killestein
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 10, 2015
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathyAnke Vennegoor, Johannis A van Rossum, Chris H Polman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 6, 2013
Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patientsJohannis A van Rossum, Anke Vennegoor, Lisanne Balk, et al.
Multiple Sclerosis and Related Disorders|June 23, 2019
Severe cutaneous adverse event in a daclizumab-treated multiple sclerosis patientJohannis A van Rossum, Marieke A D Peters, Paul van der Valk, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2018
gMS-Classifier1 does not predict disability progression in multiple sclerosisJohannis A van Rossum, Joep Killestein, Luisa M Villar, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 26, 2019
Infusion-related events during natalizumab: No need for post-infusion monitoringFloor C Loonstra, Johannis A van Rossum, Zoé LE van Kempen, et al.
Multiple Sclerosis and Related Disorders|September 24, 2019
Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumabJohannis A van Rossum, Zoé L E van Kempen, Louise Schilder, et al.
Journal of Neurology|April 21, 2019
Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturationZoé L E van Kempen, Johannis A van Rossum, Djoeke Doesburg, et al.
Multiple Sclerosis and Related Disorders|February 20, 2021
Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patientsZoé L E van Kempen, Johannis A van Rossum, Erwin Hoogervorst, et al.
Pageof 1